<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610399</url>
  </required_header>
  <id_info>
    <org_study_id>7061</org_study_id>
    <nct_id>NCT03610399</nct_id>
  </id_info>
  <brief_title>Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil</brief_title>
  <official_title>Efficacy of Three Regimens of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Evandro Chagas National Institute of Infectious Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We plan to assess the efficacy of 3 different regimens of chloroquine and primaquine for the&#xD;
      treatment of P. vivax infections in Cruzeiro do Sul, Acre, Brazil. Patients will be divided&#xD;
      in 3 different groups: treatment with regular dose of primaquine (0.5 mg/kg per day for 7&#xD;
      days) with directly observed therapy; regular dose of primaquine without directly observed&#xD;
      therapy; and increased total dose of primaquine (0.5 mg/kg per day for14 days) with directly&#xD;
      observed therapy. All patients will receive chloroquine (CQ) for three days at a daily dose&#xD;
      of approximately 25 mg/Kg in accordance with the Brazilian National Malaria Control&#xD;
      guidelines. Clinical and parasitologic parameters will be monitored over a 28-day follow-up&#xD;
      period to evaluate drug efficacy and for a total period of 168 days (24 weeks) to evaluate&#xD;
      chances of recrudescence, relapse, or reinfection. Results from this drug efficacy study will&#xD;
      be used to assist the Brazilian Ministry of Health in assessing their national malaria&#xD;
      treatment policy for P. vivax malaria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The World Health Organization recommends that antimalarial treatment policies be&#xD;
      evaluated every few years to check their efficacy. P. vivax malaria is the most common&#xD;
      species in Brazil and cases are concentrated in the Amazon Region in Brazil.&#xD;
&#xD;
      Objectives: Assess the efficacy of 3 different regimens of chloroquine and primaquine for the&#xD;
      treatment of P. vivax infections in Cruzeiro do Sul, Acre, Brazil.&#xD;
&#xD;
      Methods: An in vivo drug efficacy study will be conducted in Cruzeiro do Sul, Acre State,&#xD;
      Brazil. A total of 257 study participants ≥5 years of age with parasitologically confirmed P.&#xD;
      vivax monoinfections will be included. Patients will be divided in 3 different groups:&#xD;
      treatment with regular dose of primaquine (0.5 mg/kg per day for 7 days) with directly&#xD;
      observed therapy; regular dose of primaquine without directly observed therapy; and increased&#xD;
      total dose of primaquine (0.5 mg/kg per day for14 days) with directly observed therapy. All&#xD;
      patients will receive chloroquine (CQ) for three days at a daily dose of approximately 25&#xD;
      mg/Kg in accordance with the Brazilian National Malaria Control guidelines. Primaquine will&#xD;
      be given for 7 or 14 days under supervision or not, depending on the study group. Clinical&#xD;
      and parasitologic parameters will be monitored over a 28-day follow-up period to evaluate&#xD;
      drug efficacy and for a total period of 168 days (24 weeks) to evaluate chances of&#xD;
      recrudescence, relapse, or reinfection. Blood samples will be taken to measure the CQ levels&#xD;
      in blood on Day 7 and day of failure, if occurring in the initial 28 days of follow up. In&#xD;
      addition, a blood sample will be collected on filter paper on first day and on day of&#xD;
      suspected failure to help differentiate parasite genotypes using techniques based on&#xD;
      polymerase chain reaction. Results from this drug efficacy study will be used to assist the&#xD;
      Brazilian Ministry of Health in assessing their national malaria treatment policy for P.&#xD;
      vivax malaria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">March 12, 2019</completion_date>
  <primary_completion_date type="Actual">March 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We plan to compare 3 different regimens of primaquine for P. vivax treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled</measure>
    <time_frame>28 days</time_frame>
    <description>Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled</measure>
    <time_frame>168 days</time_frame>
    <description>Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168</measure>
    <time_frame>168 days</time_frame>
    <description>Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>P Vivax</condition>
  <condition>Malaria, Vivax</condition>
  <arm_group>
    <arm_group_label>Primaquine Regular Dose Unsupervised</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is the regular primaquine dose Brazil without directly observed therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine Regular Dose Supervised</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the regular primaquine dose in Brazil but with directly observed therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine Double Dose Unsupervised</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>Different total dose and supervision.</description>
    <arm_group_label>Primaquine Double Dose Unsupervised</arm_group_label>
    <arm_group_label>Primaquine Regular Dose Supervised</arm_group_label>
    <arm_group_label>Primaquine Regular Dose Unsupervised</arm_group_label>
    <other_name>Primaquine dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age ≥5 years 2. Body weight &lt;120 kg 3. Documented fever (axillary temperature&#xD;
             ≥37.5o C) or history of fever during the previous 48 hours in the absence of another&#xD;
             obvious cause of fever, such as pneumonia, otitis media, etc 4. Monoinfection with P.&#xD;
             vivax with parasitemia between 100 and 200,000 asexual parasites/µl as determined by&#xD;
             microscopic examination of thick and thin peripheral blood smears 5. Informed consent&#xD;
             from the patient or parent/guardian (for those &lt;18 years), assent from child (ages 7&#xD;
             to 17 years inclusive), patients 5 through 6 years old will not need an assent 6.&#xD;
             Willingness on the part of the patient to return to the clinic and/or receive home&#xD;
             visits for regular check-ups during the 24-week (168 days) follow-up period 7. Place&#xD;
             of residence within 30-45 minutes of study site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Presence of malaria danger signs&#xD;
&#xD;
               1. Unable to drink&#xD;
&#xD;
               2. Vomiting (more than twice in the previous 24 hours)&#xD;
&#xD;
               3. Recent history of convulsions (one or more in the previous 24 hours)&#xD;
&#xD;
               4. Impaired consciousness&#xD;
&#xD;
               5. Unable to sit or stand 2. Presence of signs of severe malaria (WHO criteria)&#xD;
&#xD;
               1. Cerebral malaria (unarousable coma)&#xD;
&#xD;
               2. Severe anemia (hematocrit &lt;15% or clinical signs) hemoglobin &lt;5 mg/ml) (Note: we&#xD;
                  will use hemoglobin less than 8 mg/ml as exclusion criteria)&#xD;
&#xD;
               3. Renal failure (serum creatinine &gt;3 mg/dL or clinical signs)&#xD;
&#xD;
               4. Pulmonary edema&#xD;
&#xD;
               5. Hypoglycemia (blood glucose &lt;40mg/dL or clinical signs)&#xD;
&#xD;
               6. Shock (systolic blood pressure &lt;70 mm Hg in adults; 50 mm Hg in children)&#xD;
&#xD;
               7. Spontaneous bleeding/disseminate intravascular coagulation&#xD;
&#xD;
               8. Repeated generalized convulsions&#xD;
&#xD;
               9. Acidemia/acidosis (clinical signs)&#xD;
&#xD;
              10. Macroscopic hemoglobinuria&#xD;
&#xD;
              11. Jaundice 3. Self-reported presence of other underlying chronic or severe diseases&#xD;
                  (e.g., cardiac, renal, hepatic diseases, HIV/AIDS, tuberculosis, malnutrition,&#xD;
                  psoriasis) 4. History of hypersensitivity reactions to any of the drugs being&#xD;
                  tested. Mild itching with CQ is not in itself a criterion for exclusion. This&#xD;
                  occurrence will be evaluated by the study doctor before excluding the patient for&#xD;
                  this reason alone.&#xD;
&#xD;
                  5. Use of drugs with antimalarial activity in the past 30 days. (Annex D) 6.&#xD;
                  Current pregnancy (either self-reported being pregnant at enrollment or a&#xD;
                  positive urine or plasma pregnancy test at time of enrollment), previous&#xD;
                  pregnancy is not an exclusion criteria 7. Hemoglobin &lt;8 mg/mL 8. G6PD deficiency.&#xD;
                  This will be a late exclusion criteria as soon as the results of G6PD testing&#xD;
                  becomes available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Macedo de Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital do Jurua</name>
      <address>
        <city>Cruzeiro do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <results_first_submitted>May 24, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment response</keyword>
  <keyword>efficacy</keyword>
  <keyword>primaquine</keyword>
  <keyword>chloroquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not such a plan.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03610399/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primaquine Regular Dose Unsupervised</title>
          <description>This is the regular primaquine dose (3.5 mg/kg) Brazil without directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="P2">
          <title>Primaquine Regular Dose Supervised</title>
          <description>This is the regular primaquine dose (3.5 mg/kg) in Brazil but with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="P3">
          <title>Primaquine Double Dose Unsupervised</title>
          <description>This is the double total primaquine dose (14 days) (7.0 mg/kg) in Brazil with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population of patients with vivax malaria.</population>
      <group_list>
        <group group_id="B1">
          <title>Primaquine Regular Dose Unsupervised</title>
          <description>This is the regular primaquine dose (3.5 mg/kg) Brazil without directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="B2">
          <title>Primaquine Regular Dose Supervised</title>
          <description>This is the regular primaquine dose (3.5 mg/kg) in Brazil but with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="B3">
          <title>Primaquine Double Dose Unsupervised</title>
          <description>This is the double total primaquine dose (14 days) (7.0 mg/kg) in Brazil with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="95"/>
            <count group_id="B4" value="254"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="95"/>
                    <count group_id="B4" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" lower_limit="8.1" upper_limit="79.8"/>
                    <measurement group_id="B2" value="20.3" lower_limit="5.6" upper_limit="73.9"/>
                    <measurement group_id="B3" value="23.5" lower_limit="5.4" upper_limit="64.8"/>
                    <measurement group_id="B4" value="22.4" lower_limit="5.4" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="95"/>
                    <count group_id="B4" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="96"/>
                    <count group_id="B3" value="95"/>
                    <count group_id="B4" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled</title>
        <description>Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia.</description>
        <time_frame>28 days</time_frame>
        <population>Per-protocol uncorrected analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Primaquine Regular Dose Unsupervised</title>
            <description>This is the regular primaquine dose (3.5 mg/kg) Brazil without directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
          <group group_id="O2">
            <title>Primaquine Regular Dose Supervised</title>
            <description>This is the regular primaquine dose (3.5 mg/kg) in Brazil but with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
          <group group_id="O3">
            <title>Primaquine Double Dose Unsupervised</title>
            <description>This is the double total primaquine dose (14 days) (7.0 mg/kg) in Brazil with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled</title>
          <description>Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia.</description>
          <population>Per-protocol uncorrected analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled</title>
        <description>Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia.</description>
        <time_frame>168 days</time_frame>
        <population>Per-protocol uncorrected analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Primaquine Regular Dose Unsupervised</title>
            <description>This is the regular primaquine dose (3.5 mg/kg) Brazil without directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
          <group group_id="O2">
            <title>Primaquine Regular Dose Supervised</title>
            <description>This is the regular primaquine dose (3.5 mg/kg) in Brazil but with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
          <group group_id="O3">
            <title>Primaquine Double Dose Unsupervised</title>
            <description>This is the double total primaquine dose (14 days) (7.0 mg/kg) in Brazil with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled</title>
          <description>Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia.</description>
          <population>Per-protocol uncorrected analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168</title>
        <description>Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites.</description>
        <time_frame>168 days</time_frame>
        <population>Microsatellite-corrected analysis excludes participants who, during follow-up, presented with heterologous infections (genotype different) or whose genotype could not be determined. This reduced the number of overall participants by 12 for the 'Primaquine Regular Dose Unsupervised' arm; 17 participants in the 'Primaquine Regular Dose Supervised' arm; and 8 participants in the 'Primaquine Double Dose Unsupervised' arm, in comparison to the totals in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Primaquine Regular Dose Unsupervised</title>
            <description>This is the regular primaquine dose (3.5 mg/kg) Brazil without directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
          <group group_id="O2">
            <title>Primaquine Regular Dose Supervised</title>
            <description>This is the regular primaquine dose (3.5 mg/kg) in Brazil but with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
          <group group_id="O3">
            <title>Primaquine Double Dose Unsupervised</title>
            <description>This is the double total primaquine dose (14 days) (7.0 mg/kg) in Brazil with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168</title>
          <description>Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites.</description>
          <population>Microsatellite-corrected analysis excludes participants who, during follow-up, presented with heterologous infections (genotype different) or whose genotype could not be determined. This reduced the number of overall participants by 12 for the 'Primaquine Regular Dose Unsupervised' arm; 17 participants in the 'Primaquine Regular Dose Supervised' arm; and 8 participants in the 'Primaquine Double Dose Unsupervised' arm, in comparison to the totals in the Participant Flow section.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During patient follow-up, 6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Primaquine Regular Dose Unsupervised</title>
          <description>This is the regular primaquine dose (3.5 mg/kg) Brazil without directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="E2">
          <title>Primaquine Regular Dose Supervised</title>
          <description>This is the regular primaquine dose (3.5 mg/kg) in Brazil but with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
        <group group_id="E3">
          <title>Primaquine Double Dose Unsupervised</title>
          <description>This is the double total primaquine dose (14 days) (7.0 mg/kg) in Brazil with directly observed therapy.&#xD;
Primaquine: Different total dose and supervision.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suiane Negreiros</name_or_title>
      <organization>Acre Health State Secretariat</organization>
      <phone>55 68 9983 1266</phone>
      <email>omsvalle@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

